

Sofosbuvir + Peginterferon+ Ribavirin in HCV-HIV GT 1-4

Rodriguez-Torres M, et al. J Acquir Immune Defic Syndr. 2015;68:543-9.

Sofosbuvir + PEG + RBV for HCV-HIV Coinfection

Study Features

Sofosbuvir + PEG + RBV for HCV GT 1-6 and HIV Coinfection: Features

- **Design:** Open-label, single-arm, phase 2 trial of sofosbuvir plus peginterferon alfa-2a plus ribavirin in HCV GT 1-6 with HIV coinfection
- **Setting:** single site in Puerto Rico
- **Entry Criteria**
 - Chronic HIV coinfection; HCV genotype 1-6
 - Age ≥ 21
 - HCV treatment naïve
 - On antiretroviral therapy for at least 8 weeks
 - CD4 count greater than 200 cells/mm³
 - No cirrhosis
- **Patient Characteristics**
 - N = 23 HCV-HIV coinfecting patients
 - GT1 (n=19); GT2 (n=1); GT3 (n=2); GT4 (n=1)
- **Primary End-Points**
 - Efficacy (SVR12), safety/tolerability, and impact on HIV

Sofosbuvir + PEG + RBV for HCV-HIV Coinfection

Demographics

Sofosbuvir + PEG + RBV for HCV GT 1-4 and HIV Coinfection	
Baseline Characteristics	Patients (n=23)
Age, mean (range)	47 (29-59)
Male, n (%)	18 (78.3)
Mean BMI (range)	26.3 (18.0-46.4)
Race, n (%)	
White	15 (65.2)
Black/African American	8 (34.8)
HCV Genotype, n (%)	
1a	15 (65.2)
1b	4 (17.4)
2b	1 (4.3)
3a	2 (8.7)
4	1 (4.3)
Mean CD4 count, cells/mm ³	562

Sofosbuvir + PEG + RBV for HCV-HIV Coinfection P7977-1910 Trial: Antiretroviral Regimens

Sofosbuvir + PEG + RBV for HCV GT 1-4 and HIV Coinfection	
Antiretroviral Agent	Antiretroviral Treated (n = 23)
Tenofovir-emtricitabine	23 (100%)
Efavirenz	7 (30%)
Rilpivirine	1 (4%)
Atazanavir/ritonavir	5 (22%)
Darunavir/ritonavir	4 (17%)
Raltegravir	6 (26%)

Sofosbuvir + PEG + RBV for HCV-HIV Coinfection

Week

0

12

24

**GT 1-4
Naïve**

**Sofosbuvir + Peginterferon
+ Ribavirin (n = 23)**

SVR12

Drug Dosing


Sofosbuvir: 400 mg once daily

Peginterferon alfa-2a 180 mcg per week

Ribavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg


Sofosbuvir + PEG + RBV for HCV-HIV Coinfection Results

SVR12, by Genotype



Sofosbuvir + PEG + RBV for HCV-HIV Coinfection Results

SVR12, by Antiretroviral Regimen



Sofosbuvir + PEG + RBV for HCV-HIV Coinfection

Results: Interpretation

Interpretation: “Sofosbuvir may be coadministered safely with many commonly used antiretrovirals. The addition of sofosbuvir to peginterferon–ribavirin was highly effective as assessed by SVR in HCV/HIV-coinfected patients.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.